SLC2A4 and neoplasm: We hypothesise that a treatment strategy combining an ME1 inhibitor with an inhibitor of glycolysis, such as 2-DG, or with an inhibitor of glucose transporter, such as GLUT-4 inhibitor, could result in a synergic action against the tumour regardless of tumour microenvironment.